Assessment of Carvedilol Therapy in Prevention of Heart Failure in HER2 Positive Breast Cancer Patients Receiving Trastuzumab

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

Sherafati Alborz; MEHRPOOYA MARYAM; SATTARZADEH BADKOUBEH ROYA; LARTI FARNOOSH; SHAHI FARHAD; MIRZANIA MEHRZAD; ESFANDBOD MOHSEN; SAADAT MOHAMMAD; GHASEMI MASOUD; Zebardast Jeyran

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: ACTA MEDICA IRANICA Year:2019 | Volume:57 | Issue:3 Page(s): 173-179

Download Full-Text

View:

138

Download:

Cites:

Information Journal Paper

Title

Assessment of Carvedilol Therapy in Prevention of Heart Failure in HER2 Positive Breast Cancer Patients Receiving Trastuzumab

Author(s)

Keywords

Breast cancer

Trastuzumab

Carvedilol

Cardiomyopathy

Abstract

Breast cancer is the most common cancer among the female population, and its prevalence is increasing worldwide. Trastuzumab (Herceptin) therapy improves prognosis in HER2 positive patients, but Heart Failure (HF) is one of its known complications. In this study, we aimed to assess the potential benefits of prophylactic Carvedilol therapy in patients receiving Herceptin. Sixty five patients with HER2 positive Breast cancer were enrolled in the study. All of the patients received Herceptin. Twenty seven patients also received Carvedilol 6. 25 mg twice daily, and 38 patients had usual care. Echocardiography was performed at baseline, and after three months in both groups and changes in cardiac function, parameters were compared between two groups. After 3 months, LA volume index (P=0. 012), TAPSE (P=0. 009), Tei index (P=0. 015) and Lateral Longitudinal Strain (P=0. 024) were significantly better in patients receiving Carvedilol. Carvedilol can be effective in the prevention of systolic and diastolic dysfunction following Herceptin therapy.

Cites

No record.

References

No record.

Cite

APA: Copy

Sherafati, Alborz, MEHRPOOYA, MARYAM, SATTARZADEH BADKOUBEH, ROYA, LARTI, FARNOOSH, SHAHI, FARHAD, MIRZANIA, MEHRZAD, ESFANDBOD, MOHSEN, SAADAT, MOHAMMAD, GHASEMI, MASOUD, & Zebardast, Jeyran. (2019). Assessment of Carvedilol Therapy in Prevention of Heart Failure in HER2 Positive Breast Cancer Patients Receiving Trastuzumab. ACTA MEDICA IRANICA, 57(3), 173-179. SID. https://sid.ir/paper/279073/en

Vancouver: Copy

Sherafati Alborz, MEHRPOOYA MARYAM, SATTARZADEH BADKOUBEH ROYA, LARTI FARNOOSH, SHAHI FARHAD, MIRZANIA MEHRZAD, ESFANDBOD MOHSEN, SAADAT MOHAMMAD, GHASEMI MASOUD, Zebardast Jeyran. Assessment of Carvedilol Therapy in Prevention of Heart Failure in HER2 Positive Breast Cancer Patients Receiving Trastuzumab. ACTA MEDICA IRANICA[Internet]. 2019;57(3):173-179. Available from: https://sid.ir/paper/279073/en

IEEE: Copy

Alborz Sherafati, MARYAM MEHRPOOYA, ROYA SATTARZADEH BADKOUBEH, FARNOOSH LARTI, FARHAD SHAHI, MEHRZAD MIRZANIA, MOHSEN ESFANDBOD, MOHAMMAD SAADAT, MASOUD GHASEMI, and Jeyran Zebardast, “Assessment of Carvedilol Therapy in Prevention of Heart Failure in HER2 Positive Breast Cancer Patients Receiving Trastuzumab,” ACTA MEDICA IRANICA, vol. 57, no. 3, pp. 173–179, 2019, [Online]. Available: https://sid.ir/paper/279073/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops